Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
株式のランク #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
株価
$0.15
時価総額
$4.96M
変化(1日)
0.00%
変化(1年)
0.00%
CA
取引 Intellipharmaceutics International Inc. (IPCIF)

カテゴリー

Intellipharmaceutics International Inc.(IPCIF)のP/E比率
March 2026 時点のP/E比率 TTM -1.72
Intellipharmaceutics International Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -1.72 です。2021 年末時点での P/E は -1.22 でした。
Intellipharmaceutics International Inc. の P/E 比率の履歴(1999 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) -1.72 114.53%
2022 -0.80 -34.41%
2021 -1.22 105.11%
2020 -0.60 -37.64%
2019 -0.95 734.44%
2018 -0.11 -96.12%
2017 -2.95 -59.83%
2016 -7.34 9.41%
2015 -6.71 -61.01%
2014 -17.21 155.32%
2013 -6.74 -0.93%
2012 -6.81 -29.45%
2011 -9.65 93.02%
2010 -5.00 0.00%
2009 0.00 -100.00%
2008 -8.65 152.51%
2007 -3.43 353.05%
2006 -0.76 51.93%
2005 -0.50 -9.04%
2004 -0.55 -56.22%
2003 -1.25 -35.54%
2002 -1.94 -20.97%
2001 -2.45 -27.10%
2000 -3.37 24.41%
1999 -2.71 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
10.72 -724.47%
DK
30.14 -1,856.44%
US
17.03 -1,092.58%
US
30.44 -1,873.60%
BE
38.30 -2,331.79%
NL
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。